Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label trial of cannabidivarin in patients with Rett syndrome

Trial Profile

An open label trial of cannabidivarin in patients with Rett syndrome

Planning
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs Cannabidivarin (Primary)
  • Indications Rett syndrome; Seizures
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Nov 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jan 2019, according to a GW pharmaceuticals media release.
    • 27 Nov 2018 According to a GW pharmaceuticals media release, this trial is due to commence in Q1 2019.
    • 07 Aug 2018 According to a GW pharmaceuticals media release, this trial is due to commence in Q3 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top